Molecular biomarkers of future aggressive behavior in pituitary tumors
Molecular biomarkers of future aggressive behavior in pituitary tumors
批准号:
10650948
负责人:
Andrew Lin
金额:
$24.82万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-04-15 至 2025-03-31
关键词:
AddressAggressive behaviorAlgorithmsAlkylating Antineoplastic AgentsAnterior Pituitary GlandAskenazy CellsAutopsyBehaviorBenignBiological MarkersBlindnessBrainBrain NeoplasmsCharacteristicsChromosomal LossChromosomesClinicalClinical TrialsClonalityCommunitiesConsentCopy Number PolymorphismDNA methylation profilingDataData SetDevelopmentDiagnosisDiseaseDisease ProgressionEndocrinologistEpigenetic ProcessExcisionExhibitsFutureGenesGeneticGenomeGenomicsGoalsGrowthIncidenceIndividualIndolentInstitutionIntracranial NeoplasmsInvadedIslet Cell TumorLifeMalignant - descriptorMalignant Epithelial CellMalignant NeoplasmsMethylationMolecularMorbidity - disease rateMutationNational Cancer InstituteNatural HistoryNeoplasm MetastasisNeuroendocrine TumorsNeurologic DysfunctionsNoiseOperative Surgical ProceduresOralPathway interactionsPatient-Focused OutcomesPatientsPatternPhenotypePituitary Corticotropin Secreting AdenomaPituitary Gland AdenomaPituitary NeoplasmsPituitary carcinomaPrevalenceRadiationRadiation therapyRecurrenceRegistriesReportingSEER ProgramSamplingSubgroupTimeTumor BankUnited StatesValidationWorkWorld Health Organizationadenomabiomarker validationclinical decision-makingclinical phenotypeclinically relevantcohortdensityexome sequencingfollow-uphigh riskhormone therapyimprovedlactotrophmenmolecular markermolecular subtypesmortalitynext generation sequencingnovel therapeuticspredictive markerpreventprospectiverapid growthresponseskull basestandard carestandard of caretemozolomidetumortumor registry
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
A small subset of pituitary adenomas demonstrates aggressive behavior as defined by rapid growth following
treatment, namely hormonal therapy, surgery, and radiation. Aggressive pituitary tumors are devastating, life-
limiting malignancies with two patterns of growth: (1) they can remain confined to the skull base and grow
relentlessly, resulting in progressive neurologic dysfunction or (2) they can metastasize. These tumors are
poorly studied and under-recognized in part because there are no validated biomarkers that predict future
aggressive behavior. We hypothesize that recurrent patterns of copy number variation, including a molecular
hypodiploidy phenotype, characterized by an early, clonal loss of one copy of chromosomes 1, 2, 3, 6, 8, 10, 11,
13, 15, 17, 18, 21, and 22, predict future progression following treatment with radiotherapy. Additionally, we
hypothesize that aggressive pituitary adenomas and carcinomas harbor recurrent epigenetic and genetic
alterations at a gene and pathway level that define a more aggressive molecular subtype. This foundational
work is needed so that clinicians can prospectively identify tumors with a higher malignant potential. The
identification of a biomarker of aggressive disease is critical for improving patient outcomes by preventing both
over- and undertreatment, and for clinical trial development.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金